

OFFICE OF INSPECTOR GENERAL

TEXAS HEALTH & HUMAN SERVICES COMMISSION

SYLVIA HERNANDEZ KAUFFMAN PRINCIPAL DEPUTY INSPECTOR GENERAL

August 29, 2017

US Bioservices Corporation Kelly Ratliff, Vice President 3101 Gaylord Pkwy MS: 1E E222 Frisco, Texas 75056

Dear Ms. Ratliff:

The Health and Human Services Commission (HHSC) Inspector General (IG) Audit Division conducted an audit of US Bioservices Corporation's Vendor Drug Program (VDP) claims filed by US Bioservices Corporation for reimbursement. The objectives of the audit were to determine whether US Bioservices Corporation (a) properly billed VDP for Medicaid claims submitted and (b) complied with contractual and Texas Administrative Code (TAC) requirements for the period of March 1, 2012, through February 28, 2015.

The auditors tested documentation supporting a sample of 60 claims selected from a population of 2,526 claims that US Bioservices Corporation submitted to VDP for reimbursement during the audit period. Results indicated no exceptions for the claims tested and that the claims (a) were properly billed and (b) complied with applicable contractual and TAC requirements.

The IG Audit Division conducted this audit in accordance with generally accepted government auditing standards. Those standards require that we plan and perform the audit to obtain sufficient, appropriate evidence to provide a reasonable basis for our findings and conclusions based on our audit objectives. The IG Audit Division believes that the evidence obtained provides a reasonable basis for our findings and conclusions based on our audit objectives.

No further review is necessary at this time. You should retain the records pertaining to the claims that were the subject of this audit as they may be re-audited or investigated at a future date by the State of Texas, the Centers for Medicare and Medicaid Services, or other authorities.

Thank you for your cooperation during this audit.

Sylvia Hernandez Kauffman

Principal Deputy Inspector General

Soma H. Kauffman